Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Certolizumab pegol + Cisplatin + Nivolumab + Pemetrexed Disodium|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Certolizumab pegol||Cimzia||Cimzia (certolizumab pegol) is a pegylated monoclonal antibody targeting TNF-alpha, which potentially inhibits tumor growth and metastasis (PMID: 36241629, PMID: 20190560)|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 7||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 101||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent NSCLC without EGFR or ALK alterations, in combination with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Pemetrexed Disodium||Alimta||LY231514|Ciambra|pemetrexed||Chemotherapy - Antimetabolite 14||Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04991025||Phase II||Certolizumab pegol + Cisplatin + Gemcitabine + Nivolumab Certolizumab pegol + Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Certolizumab pegol + Gemcitabine + Nivolumab Carboplatin + Certolizumab pegol + Nivolumab + Pemetrexed Disodium||Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery||Recruiting||USA||0|